| Arkansas Eye Care Vision Source | |
| 2402 Harrison St, Batesville, Arkansas 72501 | |
| (870) 793-4681 |
| Name | Arkansas Eye Care Vision Source |
|---|---|
| Organization Name | Hayden Sowers Optometry Pa |
| Location | 2402 Harrison St, Batesville, Arkansas 72501 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (870) 793-4681 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).
While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.
According to a new review, approximately 30 million Americans – about 15 percent of adults – have chronic kidney disease, a number that is expected to increase in the next 20 years due to rising obesity rates and longer lifespans, but the majority of chronic kidney disease patients aren't receiving potentially lifesaving treatment.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.
The RAND Corporation and RAND Europe have released the first-ever, state-by-state analysis (in 47 states) of the economic implications of a shift in school start times in the U.S., showing that a nationwide move to 8.30 a.m. could contribute $83 billion to the U.S. economy within a decade.
› Verified 7 days ago
| NPI Number | 1063683761 |
| Organization Name | ARKANSAS EYECARE SPECIALIST |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2402 Harrison St, Batesville, AR 72501 |
| Phone Number | 870-793-4681 |
News Archive
Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).
While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.
According to a new review, approximately 30 million Americans – about 15 percent of adults – have chronic kidney disease, a number that is expected to increase in the next 20 years due to rising obesity rates and longer lifespans, but the majority of chronic kidney disease patients aren't receiving potentially lifesaving treatment.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.
The RAND Corporation and RAND Europe have released the first-ever, state-by-state analysis (in 47 states) of the economic implications of a shift in school start times in the U.S., showing that a nationwide move to 8.30 a.m. could contribute $83 billion to the U.S. economy within a decade.
› Verified 7 days ago
News Archive
Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).
While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.
According to a new review, approximately 30 million Americans – about 15 percent of adults – have chronic kidney disease, a number that is expected to increase in the next 20 years due to rising obesity rates and longer lifespans, but the majority of chronic kidney disease patients aren't receiving potentially lifesaving treatment.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.
The RAND Corporation and RAND Europe have released the first-ever, state-by-state analysis (in 47 states) of the economic implications of a shift in school start times in the U.S., showing that a nationwide move to 8.30 a.m. could contribute $83 billion to the U.S. economy within a decade.
› Verified 7 days ago
Bryant's Investments & Holding Inc Type: Long Term Care Pharmacy Location: 2000 Harrison St, Batesville, Arkansas 72501 Phone: (870) 793-3999 | |
Jp&o Prosthetic & Orthotic Laborato Type: Prosthetic/Orthotic Supplier Location: 1699 Harrison Street, Batesville, Arkansas 72501 Phone: (870) 698-0991 | |
Davie Medical Equipment Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2705 Harrison St, Batesville, Arkansas 72501 Phone: (870) 569-1435 | |
Dr. James O. Davis Iii O.d.p.a. Type: Medicare Supplier Location: 2615 Harrison St, Batesville, Arkansas 72501 Phone: (870) 793-4400 | |
Econo Mart Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1595 Harrison St, Batesville, Arkansas 72501 Phone: (870) 793-4179 |